The burgeoning popularity of tirzepatide , initially for blood sugar control , is creating significant interest within the UK , prompting a notable shift in peptide trends. Obtaining these treatments remains a complex landscape, with public healthcare system approval currently limited and specialist practices offering therapy at a substantial price